+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology) - Drugs in Development, 2021

  • PDF Icon

    Report

  • 2145 Pages
  • October 2021
  • Region: Global
  • Global Markets Direct
  • ID: 5473103
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Lymphocytic Leukemia - Drugs In Development, 2021, provides an overview of the Acute Lymphocytic Leukemia (Oncology) pipeline landscape. Acute lymphocytic leukemia (ALL) is the cancer of the white blood cells due to the production of a large number of immature lymphocytes thus blocking the production of normal blood cells. It enters the blood stream and rapidly progress to other parts of the body such as spleen, lymph nodes and liver. Risk factors for ALL include exposure to radiation or chemicals, age, virus infections and genetic factors. Symptoms include anemia, frequent infections, easy bruising, bone pain and breathing problems. Treatment includes chemotherapy, transfusions, transplant and medications.

Report Highlights


This pipeline guide provides comprehensive information on the therapeutics under development for Acute Lymphocytic Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Acute Lymphocytic Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 6, 110, 101, 12, 9, 114, 15 and 3 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages comprises 2, 45, 39, 2, 29, 1 and 1 molecules, respectively.

Acute Lymphocytic Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Lymphocytic Leukemia (Oncology)
  • The pipeline guide reviews pipeline therapeutics for Acute Lymphocytic Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities
  • The pipeline guide reviews key companies involved in Acute Lymphocytic Leukemia (Oncology) therapeutics and enlists all their major and minor projects
  • The pipeline guide evaluates Acute Lymphocytic Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects
  • The pipeline guide reviews latest news related to pipeline therapeutics for Acute Lymphocytic Leukemia (Oncology)

Reasons to Buy


  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Find and recognize significant and varied types of therapeutics under development for Acute Lymphocytic Leukemia (Oncology)
  • Classify potential new clients or partners in the target demographic
  • Develop tactical initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics
  • Formulate corrective measures for pipeline projects by understanding Acute Lymphocytic Leukemia (Oncology) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Introduction
Acute Lymphocytic Leukemia - Overview
  • Acute Lymphocytic Leukemia - Therapeutics Development
  • Acute Lymphocytic Leukemia - Therapeutics Assessment
  • Acute Lymphocytic Leukemia - Companies Involved in Therapeutics Development
  • Acute Lymphocytic Leukemia - Drug Profiles
  • Acute Lymphocytic Leukemia - Dormant Projects
  • Acute Lymphocytic Leukemia - Discontinued Products
  • Acute Lymphocytic Leukemia - Product Development Milestones

Appendix
List of Tables
  • Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by 4SC AG, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by AbbVie Inc, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Actinium Pharmaceuticals Inc, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Actinobac Biomed Inc, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by ADC Therapeutics SA, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Adienne Pharma & Biotech SA, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Adlai Nortye Biopharma Co Ltd, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Aeglea BioTherapeutics Inc, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by AIkido Pharma Inc, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Aileron Therapeutics Inc, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by AIMM Therapeutics BV, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Aleta Biotherapeutics Inc, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Allterum Therapeutics LLC, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Amgen Inc, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Angiocrine Bioscience Inc, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Anhui Anke Biotechnology (Group) Co Ltd, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Apexian Pharmaceuticals Inc, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Applied Therapeutics Inc, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Arch Oncology Inc, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Ascentage Pharma Group International, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by AstraZeneca Plc, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Autolus Therapeutics Plc, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Avalon GloboCare Corp, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by AVM Biotechnology LLC, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Ayala Pharmaceuticals Inc, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Bayer AG, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Beam Therapeutics Inc, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Beijing Immunochina Pharmaceuticals Co Ltd, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Bellicum Pharmaceuticals Inc, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Bio-Cancer Treatment International Ltd, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Bio-Path Holdings Inc, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Bioceltech Therapeutics Ltd, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Biocure Technology Inc, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Biomea Fusion Inc, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by BioSight Ltd, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Bristol-Myers Squibb Co, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Cambridge Innovation Technologies Consulting Ltd, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by CanBas Co Ltd, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Caribou Biosciences Inc, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by CARsgen Therapeutics Ltd, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by CASI Pharmaceuticals Inc, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Cellectis SA, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Cellestia Biotech AG, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Cellipse SAS, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Cellular Biomedicine Group Inc, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Celularity Inc, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Centrymed Pharmaceutical Inc, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Century Therapeutics Inc, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Ceptur Therapeutics Inc, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Changzhou Qianhong Bio-Pharma Co Ltd, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Chengdu USino Technology Biology Co Ltd, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Chimerix Inc, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by China Immunotech (Beijing) Biotechnology Co Ltd, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by China Immunotech Co Ltd, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Chongqing Precision Biotech Co Ltd, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Clear Creek Bio Inc, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by OncoSynergy Inc, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by OncoTartis Inc, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by OncoTherapy Science Inc, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by OneChain Immunotherapeutics, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Orca Biosystems Inc, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Orgenesis Inc, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Pascal Biosciences Inc, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by PentixaPharm GmbH, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by PeproMene Bio Inc, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by PersonGen Biomedicine Suzhou Co Ltd, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Pfenex Inc, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Pfizer Inc, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Pharma Mar SA, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by PharmaEssentia Corp, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Pinotbio Inc, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Precision Biosciences Inc, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Provectus Biopharmaceuticals Inc, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by PTC Therapeutics Inc, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Regenacy Pharmaceuticals LLC, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Regeneron Pharmaceuticals Inc, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by ReguGene Co Ltd, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Retrotherapy LLC, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Zovis Pharmaceuticals, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects, 2021
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Discontinued Products, 2021

List of Figures
  • Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Top 10 Routes of Administration, 2021
  • Number of Products by Stage and Top 10 Routes of Administration, 2021
  • Number of Products by Top 10 Molecule Types, 2021
  • Number of Products by Stage and Top 10 Molecule Types, 2021

Companies Mentioned

A selection of companies mentioned in this report includes:

  • 4SC AG
  • AbbVie Inc
  • Actinium Pharmaceuticals Inc
  • Actinobac Biomed Inc
  • ADC Therapeutics SA
  • Adienne Pharma & Biotech SA
  • Adlai Nortye Biopharma Co Ltd
  • Aeglea BioTherapeutics Inc
  • AIkido Pharma Inc
  • Aileron Therapeutics Inc
  • AIMM Therapeutics BV
  • Aleta Biotherapeutics Inc
  • Allterum Therapeutics LLC
  • Amgen Inc
  • Angiocrine Bioscience Inc
  • Anhui Anke Biotechnology (Group) Co Ltd
  • Apexian Pharmaceuticals Inc
  • Applied Therapeutics Inc
  • Arch Oncology Inc